RESEARCH TRIANGLE PARK, N.C. and ROCKLEDGE, PA. - March 2, 1999 - Quintiles Oncology Therapeutics and the National Comprehensive Cancer Network (NCCN), have signed a collaboration agreement granting Quintiles Oncology Therapeutics exclusive rights within the contract research industry to use and promote the central clinical research capabilities of NCCN, including the NCCN Outcomes Database, NCCN and Quintiles Transnational Corp. (Nasdaq: QTRN) announced today.
The collaboration is designed to streamline the startup and completion of cancer clinical trials, and accelerate the development of the NCCN Outcomes Database, the largest program of its type. The database contains aggregate information on the clinical outcomes, procedures and costs associated with cancer treatment, and is used to help improve the NCCN Oncology Practice Guidelines widely used in oncology practice.
"We believe this collaboration will result in faster study startup and provide better answers sooner about the efficacy and safety of new cancer treatments," said William T. McGivney, Ph.D., Chief Executive Officer of NCCN, which comprises 17 of the world's leading academic medical centers dedicated to cancer research and treatment. "Combining the skill and knowledge of NCCN's physicians and the expertise of Quintiles Oncology Therapeutics, a global leader in accelerating the development of new anti-cancer drugs, should help bring better cancer treatments to patients sooner." The member institutions of NCCN are: University of Texas M.D. Anderson Cancer Center; H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida; Memorial Sloan-Kettering Cancer Center; Dana-Farber Cancer Institute; Fox Chase Cancer Center; Fred Hutchinson Cancer Research Center; UCSF Stanford Health Care; Johns Hopkins Oncology Center; James Cancer Hospital and Solove Research Institute at Ohio State University; Huntsman Cancer Institute at the University of Utah; City of Hope National Medical Center; UNMC/Eppley Cancer Center at the University of Nebraska Medical Center; University of Alabama at Birmingham Comprehensive Cancer Center; St. Jude Children's Research Hospital; Roswell Park Cancer Institute; Robert H. Lurie Comprehensive Cancer Center at Northwestern University; and the University of Michigan Comprehensive Cancer Center.
The agreement calls for NCCN to develop centralized clinical research services, including an Institutional Review Board (IRB) to review proposed clinical research programs, legal and contracting services, and grant bid support. The agreement allows NCCN member institutions to choose whether to participate in the trials and use the services of the collaboration. Quintiles Oncology Therapeutics will install and administer a central research data management system and investigator database, assist NCCN in developing central research administrative functions, and install the Quintiles "Collect Suite" of fax- and Internet-based data collection systems. "
Our alliance with NCCN will give our customers streamlined access to NCCN's premier academic medical centers and cancer researchers, and access to high-quality data in as close to real time as current technology allows," said Glenn Bilawsky, Executive Vice President of Quintiles Oncology Therapeutics. "This combination of expertise, information and speed is one of the most powerful tools we have to defeat cancer."
The National Comprehensive Cancer Network's web site address is www.nccn.org.
Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization services to the pharmaceutical, biotechnology and medical device industries. Quintiles also provides healthcare policy consulting and health information management services to healthcare and governmental organizations worldwide. Quintiles is headquartered near Research Triangle Park, North Carolina. Quintiles operates through specialized work groups dedicated to meeting customers' individual needs and has more than 15,000 employees worldwide and offices in 30 countries.
Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the ability of the combined businesses to be integrated with Quintiles' current operations, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, and the actual costs of combining the businesses. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.